Zenas BioPharma's Obexelimab meets primary endpoint in IgG4-RD flare reduction trial.

Obexelimab met the primary endpoint, reducing IgG4-RD flare risk by 56%, and all four key secondary efficacy endpoints. It was well tolerated with no new safety signals. Zenas plans to submit a Biologics License Application to the FDA in Q2 2026 and a Marketing Authorization Application to the EMA in H2 2026. The company will host a conference call today at 8:00 a.m. ET.